Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.44 |
| ▸ | RELA | Q04206 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988935 | 1.00 | GAA (0.49) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL7097599 | 0.91 | BTK (0.51) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL8325782 | 0.91 | BTK (0.51) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL25183923 | 0.85 | GAA (0.40) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL6815007 | 0.84 | EPHX2 (0.59) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL3735359 | 0.84 | EPHX2 (0.59) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL15595143 | 0.84 | EPHX2 (0.59) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL18502932 | 0.83 | CTSK (0.47) | GAAEPHX2CTSKBTKKDM1A | |
| SCHEMBL452060 | 0.80 | GAA (0.54) | GAAEPHX2CTSKBTKNFKB1 | |
| SCHEMBL56856 | 0.78 | EPHX1 (0.53) | GAAEPHX2CTSKBTKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4514473-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024131942-A1 | CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-06-27 | — | — | WO | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-112225724-B | Benzimidazole compound kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-112250669-B | Benzimidazole compound kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-112250669-A | Benzimidazole compound kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112225724-A | Benzimidazole compound kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-109963842-B | Benzimidazole compound kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-11-03 | — | — | CN | disclosed |
| WO-2018045956-A1 | BENZIMIDAZOLE COMPOUND KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | GAA 3440/4885EPHX2 3901/4885CTSK 1480/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | GAA 3440/4885EPHX2 3901/4885CTSK 1480/4885 |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | GAA 3440/4885EPHX2 3901/4885CTSK 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.